Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
Barreiro
P
P
Soriano
V
V
Valencia
E
E
Díaz
B
B
González-Lahoz
J
J
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D015994:Incidence; D010195:Pancreatitis / Q000139:chemically induced / Q000453:epidemiology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine; D006918:Hydroxyurea